Amendments to the Specification

Please replace the Title with the Title below:

SENSITIVE DETECTION OF WILD-TYPE AND MUTANT EGFR IN BIOLOGICAL SAMPLES

Please amend the last paragraph on page 3 as follows:

The present invention involves such an assay. In the present invention, an EGFRvIII-specific ELISA (enzyme-linked immunosorbent assay) was developed using a combination of polyclonal and monoclonal antibodies directed against the deletion junction domain. In the present invention, an ELISA specific for wild-type EGFR only (not EGFRvIII) was also developed.

Please amend the paragraph on page 3, line 20, as follows:

Because EGFRvIII is tumor specific, an assay which can detect and quantify EGFRvIII in urine, serum/plasma, CSF (cerebrospinal fluid), amniotic fluid, breast secretions, lung sputum, and tumor cell extracts may be of critical importance in the early detection of various cancers, and also in prognosis, monitoring, and response to therapy. In addition, this assay could serve in the selection of cancer patients for novel mutant EGF-directed anticancer therapies, such as a vaccine (7), antibody-toxin conjugate (11), or EGFRvIII-specific tyrosine kinase inhibitors (12).

Please insert the following new paragraph at page 6, between lines 5 and 6:

In one embodiment, an epitope of EGFRvIII comprises a peptide of the sequence LEEKKGNYVVTDHC (SEQ ID NO:1), EKKGNYVV (SEQ ID NO:5) or KGN (SEQ ID NO:6), and an epitope of EGFR comprises a peptide of the sequence LEEKKC (SEQ ID NO:2), NYVVTDHC (SEQ ID NO:3), EKK (SEQ ID NO:7), NYVVTDH (SEQ ID NO:8) or NYV (SEQ ID NO:9).